Glutathione: a novel treatment target in psychiatry

Trends in Pharmacological Sciences

Volumn 29, Issue 7, 2008, Pages 346-351

  Berk, Michael ^a,b,c   Ng, Felicity ^a   Dean, Olivia ^c   Dodd, Seetal ^a   Bush, Ashley I ^c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE;

ANTIOXIDANT ACTIVITY; ARTICLE; MENTAL DISEASE; NEUROTRANSMISSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

GLUTATHIONE; HUMANS; MENTAL DISORDERS; OXIDATIVE STRESS;

EID: 45849098291     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.05.001     Document Type: Article

References (63)

1. Looney J.M., and Childs H.M. The lactic acid and glutathione content of the blood of schizophrenic patients. J. Clin. Invest. 13 (1934) 963-968
2. Dringen R., and Hirrlinger J. Glutathione pathways in the brain. Biol. Chem. 384 (2003) 505-516
3. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
4. Baxter Jr. L.R., et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch. Gen. Psychiatry 42 (1985) 441-447
5. Karry R., et al. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 55 (2004) 676-684
6. Berk M., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 434 (2007) 41-49
7. Malhi G.S., and Berk M. Does dopamine dysfunction drive depression?. Acta Psychiatr. Scand. Suppl. 433 (2007) 116-124
8. Chen L., et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28 (2008) 425-433
9. Larouche A., et al. Subacute H2O2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 62 (2008) 70-73
10. Jia, Z. et al. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. Neurochem. Res. (in press)
11. Akyol O., et al. The indices of endongenous oxidative and antioxidative processes in plasma from schizophrenic patients; the possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 995-1005
12. Kuloglu M., et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 20 (2002) 171-175
13. Bilici M., et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64 (2001) 43-51
14. Altuntas I., et al. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med. 38 (2000) 1277-1281
15. Andreazza A.C., et al. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41 (2007) 523-529
16. Simon N.M., et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol. Psychiatry 60 (2006) 432-435
17. Andreazza A.C., et al. DNA damage in rats after treatment with methylphenidate. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 1282-1288
18. Herken H., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch. Med. Res. 38 (2007) 247-252
19. Machado-Vieira R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421 (2007) 33-36
20. Srivastava N., et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl.) 158 (2001) 140-145
21. Ben Othmen L., et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 155-159
22. Herken H., et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 6 (2001) 66-73
23. Gergerlioglu H.S., et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 697-702
24. Dakhale G., et al. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 49 (2004) 205-209
25. Kapczinski F., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 32 (2008) 675-692
26. Durmaz A., and Dikmen N. Homocysteine effects on cellular glutathione peroxidase (GPx-1) activity under in vitro conditions. J. Enzyme Inhib. Med. Chem. 22 (2007) 733-738
27. Sugden C. One-carbon metabolism in psychiatric illness. Nutr. Res. Rev. 19 (2006) 117-136
28. Bolt M.J., et al. Critical role of vitamin D in sulfate homeostasis: regulation of the sodium-sulfate cotransporter by 1,25-dihydroxyvitamin D3. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E744-E749
29. Tsao S.M., et al. Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr. Cancer 59 (2007) 8-13
30. Berk M., et al. Vitamin D deficiency may play a role in depression. Med. Hypotheses 69 (2007) 1316-1319
31. Pillai A., et al. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 41 (2007) 372-386
32. Wang H., et al. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 81 (2005) 572-580
33. Cui J., et al. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144 (2007) 1447-1453
34. Lee C.S., et al. Antioxidant effect of phenelzine on MPP+-induced cell viability loss in differentiated PC12 cells. Neurochem. Res. 28 (2003) 1833-1841
35. Eren I., et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem. Res. 32 (2007) 497-505
36. Saadat M., et al. Genetic polymorphism of glutathione S-transferase T1: a candidate genetic modifier of individual susceptibility to schizophrenia. Psychiatry Res. 153 (2007) 87-91
37. Tosic M., et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 79 (2006) 586-592
38. Gysin R., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16621-16626
39. Hashimoto T., et al. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 135 (2005) 5-9
40. Akyol O., et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 123-131
41. Marchbanks R.M., et al. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr. Res. 65 (2003) 33-38
42. Prabakaran S., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9 (2004) 684-697 643
43. Benes F.M., et al. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol. Psychiatry 11 (2006) 241-251
44. McQuillin A., et al. Fine mapping of a susceptibility locus for bipolar and genetically related unipolar affective disorders, to a region containing the C21ORF29 and TRPM2 genes on chromosome 21q22.3. Mol. Psychiatry 11 (2006) 134-142
45. Arvindakshan M., et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 62 (2003) 195-204
46. Dakhale G.N., et al. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl.) 182 (2005) 494-498
47. Zhang X.Y., et al. A double-blind, placebo-controlled trial of extract of ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 62 (2001) 878-883
48. Berger, G.E. et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacol. (in press)
49. Berk, M. et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry (in press)
50. Berk, M. et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry (in press)
51. LaRowe S.D., et al. Is cocaine desire reduced by N-acetylcysteine?. Am. J. Psychiatry 164 (2007) 1115-1117
52. Grant J.E., et al. N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol. Psychiatry 62 (2007) 652-657
53. Lafleur D.L., et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl.) 184 (2006) 254-256
54. Odlaug B.L., and Grant J.E. N-acetyl cysteine in the treatment of grooming disorders. J. Clin. Psychopharmacol. 27 (2007) 227-229
55. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21 (2007) 1-11
56. Yao J.K., et al. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
57. Gregor B., et al. Neuroprotection in emerging psychotic disorders. Early Interv. Psych. 1 (2007) 114-127
58. De Vries N., and De Flora S. N-acetyl-l-cysteine. J. Cell. Biochem. Suppl. 17F (1993) 270-277
59. Dringen R., and Hamprecht B. N-acetylcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain. Neurosci. Lett. 259 (1999) 79-82
60. Farr S.A., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 84 (2003) 1173-1183
61. Andreassen O.A., et al. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 11 (2000) 2491-2493
62. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 97 (2006) 1634-1658
63. Ng, F. et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. (in press)